Synthelabo

Other

Rhone-poulenc Sante

Icilio A Cavero

Salomon Z Langer

Philippe Michel Manoury

Henry Najer

Don Pierre Giudicelli

Peter Hicks

Billie M York

Jean-Claude Muller

Patrick Andre Lardenois

Jean Louis Binet

Bogdan Iliesco-Branceni

Jean Pierre Lefevre

Jean-Louis Cazor

Francois Elkik

Serge Mondot

Application of N-Methyl-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxide, in the form of a racemic mixture of the 1S,2S and 1R,2R isomers or in the form of the 1R,2R isomer, to the preparation of a medicinal product intended for the treatment of coronary insufficiency.

N-methyl-2-(3-pyridyl)-tetrahydrothio-pyran-2-carbothioamide 1-oxide to

Compositions of diltiazem and angiotensin-converting enzyme inhibitor useful for the treatment of hypertension, cardiac insufficiency and coronary insufficiency.

Pharmaceutical composition containing diltiazem and

Pharmaceutical compositions containing, by way of active substance, a combination of an alpha-blocker and a calcium antagonist. The composition is useful in treating cardiovascular disorders, especially hypertension.

Pharmaceutical compositions

2-dipropylamino-5 or -7-formylamino-6-hydroxy-1,2,3-4-tetrahydronaphthalene and their pharmaceutically acceptable salts are useful as antiglaucoma agents.

1,2,3,4-tetrahydronaphthalene derivatives used as antiglaucoma agents

2-Dipropylamino-5 or -7-formylamino-6-hydroxy-1,2,3-4-tetrahydronaphthalene and their pharmaceutically acceptable salts are useful as anti-ulcer agents.

Anti-ulcer agents

A method is provided of treating glaucoma in a patient which comprises administering, preferably as eye drops, an effective amount of the compound ##STR1## which is preferably in the form of its hydrochloride. The compound is administered preferably in the form of a sterile pharmacologically acceptable solution which contains from 0.1 to 5, and more preferably 0.1 to 2.0, percent by weight of said compound. The patient preferably obtains the anti-glaucoma agent in the form of a kit which comprises the sterile pharmacologically acceptable solution and an eyedropper for dispensing said sterile pharmacologically acceptable solution to the affected eyes of a patient suffering from glaucoma.

Method of lowering intraocular pressure using phenylimino-imidazoles

Pyridine derivatives of the formula: ##STR1## wherein R represents a group R.sub.1 O(CH.sub.2).sub.2 --, in which R.sub.1 is a (C.sub.3-6)cycloalkyl radical, a (C.sub.3-6)cycloalkyl-(C.sub.1-4)alkyl radical or allyl, and R' represents isopropyl or tert.-butyl, are new compounds useful in therapy in the treatment of cardiovascular maladies.

Certain 2,5-disubstituted pyridine derivatives producing

The invention provides phenol ethers of the formula: ##STR1## wherein

Phenol ethers

The invention provides phenol ethers of the formula: ##STR1## wherein R is branched C.sub.3-4 alkyl, C.sub.3-4 cycloalkyl, branched cyano(C.sub.3-4 alkyl), phenyl(C.sub.2-3 alkyl), halophenyl(C.sub.2-3 alkyl), (C.sub.1-4 alkoxy)phenyl(C.sub.2-4 alkyl), or (C.sub.1-4 acyl)amino(C.sub.1-4 alkyl),

The invention provides compounds of formula ##STR1## wherein A and B are hydrogen and R is hydrogen or cycloalkyl, or A and B together form an additional bond and R is cycloalkyl or cycloalkyl-alkyl. Useful in treating pathological disturbancies involving an anoxia factor.

Growing community of inventors

Paris, France

Icilio A Cavero